Status
Conditions
Treatments
About
In current clinical practice, women with biopsy proven breast cancer can be sent for breast magnetic resonance imaging (MRI) or contrast enhanced mammography (CEM) prior to surgery in order to delineate the extent of a known cancer and / or assess for the presence of occult secondary cancers. This study seeks to compare the global costs (based on actual reimbursement rates) of CEM/breast MRI, downstream imaging testing, and diagnostic procedures in women randomized to breast MRI versus CEM. Secondary goals are to compare patient preferences for CEM vs MRI and clinically relevant outcomes (e.g. conversion from lumpectormy to mastecomy).
Full description
This is a pilot randomized controlled trial comparing the global costs of two standard of care imaging techniques in patients with a new breast cancer diagnosis and planned breast conservation surgery. Patients enrolled in this study will be randomized to either CEM or breast MRI. The purpose of this study is to compare the global costs (based on actual reimbursement rates) of initial imaging modality (CEM or breast MRI), downstream imaging related to breast cancer evaluation, and diagnostic breast procedures in women randomized to breast MRI versus CEM.
Secondary endpoints include assessment of patient's reported satisfaction with the initial imaging technique received (CEM versus MRI), quantifying differences in health-related quality of life (as assessed by the patient reported Euro quality of life 5D questionnaire), rate of conversion from planned lumpectomy to mastectomy, and rate of re-operation for positive margins.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Planned neoadjuvant chemotherapy
Patients that are medically unstable
Pregnancy
Patients with known contraindication to contrast mammography, including:
Patients with known contraindication to Breast MRI including:
Patients unable to read and understand English or Spanish (i.e. an inability to complete study questionnaires)
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Central trial contact
Michael Morris, MD; Andrea Arellano, BS, CCRP
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal